Management of Multiple Embolization Arising From Atrial Myxoma

Zhang, Tao; Zhang, Xiaoming; Zhang, Xuemin; Jiang, Jingjun; Chen, Jian; Zhou, Bingying

doi:10.1016/j.athoracsur.2011.12.090

Cited by 10 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The middle cerebral artery and left hemisphere territory were the predominant locations for myxoma‐related cerebral embolism in our patients. Although most embolic events related to cardiac myxomas involve the cerebral arteries; emboli also may involve renal, coronary, or lower limb arteries . Cardiac catheterization should be carried out in all patients with angina pectoris regardless of age and the presence or absence of risk factors, to rule out cardiac emboli.…”

Section: Discussionmentioning

confidence: 99%

“…Although most embolic events related to cardiac myxomas involve the cerebral arteries; emboli also may involve renal, coronary, or lower limb arteries. 21 Cardiac catheterization should be carried out in all patients with angina pectoris regardless of age and the presence or absence of risk factors, to rule out cardiac emboli. Coronary angiography may show the hypovascularity of the polypoid type of myxoma which has a higher incidence of embolic events.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes following embolization in patients with cardiac myxoma

Boyacıoğlu

Kalender²,

Dönmez

et al. 2017

J Card Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Outcomes following embolization in patients with cardiac myxoma

Boyacıoğlu

Kalender²,

Dönmez

et al. 2017

J Card Surg

View full text Add to dashboard Cite

show abstract

“…Surgery should be done as soon as possible after the diagnosis since patients are at risk of embolization. [8][9][10] Important surgical principle in the operative field is minimal handling of the cardiac chambers to prevent tumour emboli and complete excision of tumour with a cuff of normal endocardium.…”

Section: Discussionmentioning

confidence: 99%

Left atrial myxoma causing severe mitral regurgitation

et al. 2018

View full text Add to dashboard Cite

Myxomas are the most common benign tumours of the heart, majority of them arise from left atrium. They can have varied presentations, with asymptomatic patients to be picked up in routine screening at one end of spectrum to dangerous embolic manifestations at the other end of the spectrum. We report a case of left atrial myxoma distorting the mitral valve apparatus causing severe eccentric mitral regurgitation. Patient underwent complete surgical excision of the tumour along with mitral valve repair.

show abstract

“…Advances in the CTC field in the last 8 years are to a great extent due to the release of the first and only FDA-cleared CTC capture and detection platform, CellSearch, in 2004[Cristofanilli et al, 2004Zhang et al, 2012]. Despite all of the interest in this field and the numerous second-generation technologies available today, the CellSearch system remains the only system that has been through the rigorous analytical and clinical validation necessary for FDA clearance [Budd et al, 2006;Riethdorf et al, 2007;Cohen et al, 2008;de Bono et al, 2008].…”

Section: Circulating Tumor Cells (Ctcs) As a Reliable Easily Accessimentioning

confidence: 99%

Quest for the Ideal Cancer Biomarker: An Update on Progress in Capture and Characterization of Circulating Tumor Cells

Harris¹,

Stocum

Roberts

et al. 2013

Drug Development Research

View full text Add to dashboard Cite

Preclinical Research The quest for a well‐validated, non‐invasive biomarker to aid in clinical decision making has remained elusive in the cancer space over the last 30 years. Much promise has been attached to circulating tumor cells (CTCs) as prognostic, predictive, and pharmacodynamic biomarkers with the potential to eliminate the need for invasive tumor biopsies and improve on the clinical value of other circulating tumor markers. The CellSearch® system (Veridex, LLC., Raritan, NJ, USA) cleared the U.S. Food and Drug Administration when the presence of CTCs was shown to have prognostic significance in patients with breast, prostate, and colorectal cancer. However, CTCs are not, at present, routinely being used in the clinic to guide treatment decisions. This paper discusses key attributes that a biomarker must possess, the status of other potential cancer biomarkers, and advancements in the capture and characterization of CTCs that will enable actualization of their potential as a reliable and efficient biomarker of disease diagnosis, progression, and response to therapy in the clinic.

show abstract

Management of Multiple Embolization Arising From Atrial Myxoma

Cited by 10 publications

References 10 publications

Outcomes following embolization in patients with cardiac myxoma

Outcomes following embolization in patients with cardiac myxoma

Left atrial myxoma causing severe mitral regurgitation

Quest for the Ideal Cancer Biomarker: An Update on Progress in Capture and Characterization of Circulating Tumor Cells

Contact Info

Product

Resources

About